# Remepy Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/remepy-health

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.remepy.com
- Total disclosed funding: $47M
- Latest round: Series A (Aug 12, 2026)
- Investors on record: 16

## About

Founded in 2022 and based in New York, US, Remepy, Inc. offers hybrid drugs that combine digital molecule software for neuro-endocrine and neuro-immunological systems. In May 2024, Remepy, Inc. raised USD 10 million in seed funding led by investor NFX, with participation from other investors Vine Ventures, PsyMed Ventures, and Firstime Ventures. TechAviv, Supernode Ventures, Fresh.fund, Samsung Next Ventures, StageNext, and 97212 Ventures. In August 2026, Remepy, Inc. raised USD 36 million in series A funding co-led  M Ventures and O.G. Venture Partners, with participation from IT-Farm Corporation, Key 1 Capital, Qumra Capital,  NFX, 97212 Ventures, Fresh.fund, PsyMed Ventures, TechAviv, and Vine Ventures. The company plans to utilize August 2026 funding to expand its drug development pipeline, support pharmaceutical partnerships, and advance late-stage clinical trials for its Parkinson’s disease treatment. Remepy was founded by Dr. Michal Tsur, Or Shoval, Prof. Amir Amedi, Dr. Nira Saporta, and Dr. Shahar Shelly, with Dr. Michal Tsur and Or Shoval serving as Co-CEOs, Prof. Amir Amedi as Chief Scientific Officer, Dr. Nira Saporta as Chief Therapeutics Officer, and Dr. Shahar Shelly as Chief Medical Officer.

Remepy's core product is a hybrid drug, a pharmaceutical drug targeting a specific medical condition. Additionally, the company also offers an app that features personalised, non-invasive cognitive, psychological, and behavioural exercises. The exercises include memory challenges, spatial navigation tasks, or mindfulness exercises, all tailored to the specific drug and the patient's condition. The app functions as a digital treatment protocol, providing patients with daily interventions and tracking their progress. It also gathers feedback and activity data, allowing the app to adjust the programme based on the patient's needs and responses.

## Funding rounds

- Series A, Aug 12, 2026, $36M — IT-Farm Corporation, M Ventures, Qumra Capital, NFX, TechAviv, O.G. Venture Partners, Fresh.fund, Vine Ventures, PsyMed Ventures, Key 1 Capital, 97212 Ventures, Tadmor Group
- Seed, May 1, 2024, $11M — Firstime, NFX, Samsung NEXT Ventures, Supernode Ventures, TechAviv, Fresh.fund, Vine Ventures, PsyMed Ventures, 97212 Ventures, StageNext

## Investors

- Firstime (https://capitalatlas.ai/funds/firstime) — Seed
- NFX (https://capitalatlas.ai/funds/nfx) — Seed, Series A
- Samsung NEXT Ventures (https://capitalatlas.ai/funds/samsung-next-ventures) — Seed
- Supernode Ventures (https://capitalatlas.ai/funds/supernode-ventures) — Seed
- TechAviv (https://capitalatlas.ai/funds/techaviv) — Seed, Series A
- Fresh.fund (https://capitalatlas.ai/funds/fresh-fund) — Seed, Series A
- Vine Ventures — Seed, Series A
- PsyMed Ventures (https://capitalatlas.ai/funds/psymed-ventures) — Seed, Series A
- 97212 Ventures (https://capitalatlas.ai/funds/97212-ventures) — Seed, Series A
- StageNext (https://capitalatlas.ai/funds/stagenext) — Seed
- IT-Farm Corporation (https://capitalatlas.ai/funds/it-farm-corporation) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A
- Qumra Capital (https://capitalatlas.ai/funds/qumra-capital) — Series A
- O.G. Venture Partners (https://capitalatlas.ai/funds/o-g-venture-partners) — Series A
- Key 1 Capital (https://capitalatlas.ai/funds/key-1-capital) — Series A
- Tadmor Group — Series A